We thank Dr Fraunfelder for his comments and discussion of cryotherapy as an adjunctive treatment for pterygia. Based on the established requirements of an Ophthalmic Technology Assessment Committee (OTAC) publication, we were unable to include the top…
Category: Peer-reviewed
Reply
We appreciate the comments of García-González and Teus on our article. In the study cohort, less than 17% of the patients were dissatisfied with the outcome. It is to be noticed that the Parinaud (p) scale is a measurement at 33 cm (not at 35 cm as…
Liquid Nitrogen Cryotherapy of Pterygia
The January 2013 issue of Ophthalmology includes an article by Kaufman et al that provides an excellent review of the surgical options and adjuvants used in surgery for pterygia. Labeled as a “Report by the American Academy of Ophthalmology,” the …
Uncorrected Binocular Performance after Biaspheric Ablation Profile (PresbyMAX) for Presbyopic Corneal Treatment
Surgical correction of presbyopia continues to be one of the biggest challenges for refractive surgeons. We have read with great interest the article by Baudu and associates about the postoperative binocular visual results of LASIK using PresbyMAX, a c…
The Diagnostic Utility of Anterior Chamber Paracentesis for Polymerase Chain Reaction in Anterior Uveitis
We read with interest the article by Anwar and associates on diagnostic utility of polymerase chain reaction (PCR) in anterior uveitis. The study addresses an important diagnostic challenge in the management of infectious anterior uveitis. However, it …
Consolidated Financial Statements
Leprosy and the Germ Theory
The germ theory of disease, one of the great accomplishments of science, was not established for two centuries after Anton van Leeuenhoek in 1674 saw microscopic, motile “animalcules” in stagnant pond water. These were relatively large single-celle…
Contents
Contents
This Issue At A Glance
Tozer et al (p. 2029) evaluated the effectiveness of rescue therapy in eyes with neovascular age-related macular degeneration (AMD) that failed monotherapy with intravitreal injections of bevacizumab or ranibizumab. They found that the combination of …
Reply
Thank you very much, Dr. Khawaja Khalid Shoaib, for your interest in our article, Posterior Iris-claw Aphakic Intraocular Lens Implantation in Children. We agree with Dr. Shoaib regarding the rather short 31-month average follow-up in our study. The…
Author reply
Dear Editor: We thank Drs Bateman and Silva for their comments. We share their belief in the importance of genetic counseling and written documentation when caring for families affected with genetic diseases, which is why we included genetic counseli…
A Simple Vista en Este Número
Tozer y otros (p. 2029) evaluaron la efectividad de la terapia de rescate en ojos con degeneración macular neovascular relacionada con la edad (AMD) que no respondía a la monoterapia con inyecciones de bevacizumab o ranibizumab a intervalos. Determin…
Clinician-Scientists in Ophthalmology Revisited
Clinician-scientists play a vital role in ophthalmology in translating between clinical practice and discovery research. They transform their clinical observations into laboratory investigations and help to push their and others’ basic research toward …
期刊一览
Tozer (p. 2029) 等人评估了新生血管性年龄相关性黄斑变性 (AMD) 患眼行补救治疗的有效性，这些患眼行单药治疗（玻璃体腔注射贝伐单抗或雷珠单抗）失败。他们发现，联合光动力治疗(PDT)及抗
Erratum
With apologies from the editorial office, the Correspondence entitled, “Gene Expression Profiling vs. TNM Classification,” which printed in the May 2013 issue (Ophthalmology 2013;120:1109) erroneously included a statement that the authors of the or…
Measuring Contrast Sensitivity Using the M&S Smart System II versus the Pelli-Robson Chart
Contrast sensitivity (CS) refers to the ability of the visual system to detect differences in luminance (i.e., brightness) between an object and its background. Assessment of CS provides valuable information in the early detection and monitoring of ocu…
Mutations in the Mevalonate Kinase (MVK) Gene Cause Nonsyndromic Retinitis Pigmentosa – Corrected Proof
Objective: Retinitis pigmentosa (RP) is a clinically and genetically heterogeneous disorder characterized by night blindness and peripheral vision loss, and in many cases leads to blindness. Despite extensive knowledge about genes involved in the patho…
High Prevalence of Peripheral Retinal Vascular Anomalies in Family Members of Patients with Familial Exudative Vitreoretinopathy – Corrected Proof
Objective: To describe the prevalence and severity of familial exudative vitreoretinopathy (FEVR) in asymptomatic relatives of known symptomatic FEVR patients.Design: Uncontrolled and retrospective case series at a single tertiary referral vitreoretina…
Intravitreal Aflibercept Injection for Macular Edema Resulting from Central Retinal Vein Occlusion: One-Year Results of the Phase 3 GALILEO Study – Corrected Proof
Purpose: To evaluate the efficacy and safety of intravitreal aflibercept injections for treatment of macular edema secondary to central retinal vein occlusion (CRVO).Design: A randomized, multicenter, double-masked phase 3 study.Participants: A total of 177 treatment-naive patients with macular edema secondary to CRVO were randomized in a 3:2 ratio.Methods: Patients received either 2-mg intravitreal aflibercept or sham injections every 4 weeks for 20 weeks. From week 24 to 48, the aflibercept group received aflibercept as needed (pro re nata [PRN]), and the sham group continued receiving sham injections.Main Outcome Measures: The primary efficacy end point was the proportion of patients who gained 15 letters or more in best-corrected visual acuity (BCVA) at week 24. This study reports week 52 results including the proportion of patients who gained 15 letters or more in BCVA and the mean change from baseline BCVA and central retinal thickness. Efficacy end points at week 52 were all exploratory.Results: At week 52, the mean percentage of patients gaining 15 letters or more was 60.2% in the aflibercept group and 32.4% in the sham group (P = 0.0004). Aflibercept patients, compared with sham patients, had a significantly higher mean improvement in BCVA (+16.9 letters vs. +3.8 letters, respectively) and reduction in central retinal thickness (−423.5 μm vs. −219.3 μm, respectively) at week 52 (P < 0.0001 for both). Aflibercept patients received a mean of 2.5 injections (standard deviation, 1.7 injections) during PRN dosing. The most common ocular adverse events in the aflibercept group were related to the injection procedure or the underlying disease, and included macular edema (33.7%), increased intraocular pressure (17.3%), and eye pain (14.4%).Conclusions: Treatment with intravitreal aflibercept provided significant functional and anatomic benefits after 52 weeks as compared with sham. The improvements achieved after 6 monthly doses at week 24 largely were maintained until week 52 with as-needed dosing. Intravitreal aflibercept generally was well tolerated.Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references.